ARN 75092
Alternative Names: ARN-75092Latest Information Update: 16 Jan 2024
At a glance
- Originator Arisan Therapeutics
- Developer Arisan Therapeutics; National Institute of Allergy and Infectious Diseases
- Class Antivirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Ebola virus infections
Most Recent Events
- 13 Sep 2023 Early research in Ebola virus infections in USA (PO) before September 2023 (Arisan Theapeutics pipeline, September 2023)